Total Payments
$770.09
2021 Payments
$271.68
Companies
12
Transactions
25
Medicare Patients
1,478
Medicare Billing
$413,701
Payment Breakdown by Category
Food & Beverage$648.84 (84.3%)
Education$121.25 (15.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $648.84 | 21 | 84.3% |
| Education | $121.25 | 4 | 15.7% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Mallinckrodt Hospital Products Inc. | $161.55 | 7 | $0 (2021) |
| Relypsa, Inc. | $130.40 | 3 | $0 (2018) |
| AbbVie, Inc. | $91.02 | 1 | $0 (2017) |
| Novo Nordisk Inc | $90.44 | 1 | $0 (2021) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $85.92 | 1 | $0 (2019) |
| Cumberland Pharmaceuticals, Inc. | $61.98 | 4 | $0 (2018) |
| Keryx Biopharmaceuticals, Inc. | $37.38 | 2 | $0 (2017) |
| AstraZeneca Pharmaceuticals LP | $32.82 | 1 | $0 (2019) |
| Mallinckrodt Enterprises LLC | $24.79 | 2 | $0 (2019) |
| Daiichi Sankyo Inc. | $23.35 | 1 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2021 | $271.68 | 9 | Mallinckrodt Hospital Products Inc. ($161.55) |
| 2020 | $23.35 | 1 | Daiichi Sankyo Inc. ($23.35) |
| 2019 | $143.53 | 4 | Boehringer Ingelheim Pharmaceuticals, Inc. ($85.92) |
| 2018 | $40.86 | 3 | Relypsa, Inc. ($15.24) |
| 2017 | $290.67 | 8 | Relypsa, Inc. ($115.16) |
All Payment Transactions
25 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/27/2021 | Novo Nordisk Inc | RYBELSUS (Drug) | Food and Beverage | In-kind items and services | $90.44 | General |
| Category: Diabetes | ||||||
| 10/01/2021 | Aurinia Pharma U.S., Inc. | LUPKYNIS (Drug) | Education | In-kind items and services | $19.69 | General |
| Category: LUPUS NEPHRITIS | ||||||
| 07/13/2021 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $17.67 | General |
| Category: IMMUNOLOGY | ||||||
| 06/23/2021 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $17.96 | General |
| Category: IMMUNOLOGY | ||||||
| 06/03/2021 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Education | In-kind items and services | $57.99 | General |
| Category: IMMUNOLOGY | ||||||
| 05/28/2021 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $18.21 | General |
| Category: IMMUNOLOGY | ||||||
| 05/11/2021 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $14.96 | General |
| Category: IMMUNOLOGY | ||||||
| 03/17/2021 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $13.70 | General |
| Category: IMMUNOLOGY | ||||||
| 03/05/2021 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $21.06 | General |
| Category: IMMUNOLOGY | ||||||
| 11/04/2020 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $23.35 | General |
| Category: Anemia | ||||||
| 10/28/2019 | Mallinckrodt Enterprises LLC | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $12.72 | General |
| Category: AUTOIMMUNE AND RARE DISEASE | ||||||
| 07/19/2019 | Mallinckrodt Enterprises LLC | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $12.07 | General |
| Category: AUTOIMMUNE AND RARE DISEASE | ||||||
| 05/07/2019 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Education | In-kind items and services | $32.82 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 03/27/2019 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $85.92 | General |
| Category: DIABETES | ||||||
| 09/20/2018 | Otsuka America Pharmaceutical, Inc. | SAMSCA (Drug) | Education | In-kind items and services | $10.75 | General |
| Category: NEPHROLOGY | ||||||
| 08/30/2018 | Cumberland Pharmaceuticals, Inc. | Vaprisol (Drug) | Food and Beverage | In-kind items and services | $14.87 | General |
| Category: Nephrology | ||||||
| 01/11/2018 | Relypsa, Inc. | Veltassa (Drug) | Food and Beverage | In-kind items and services | $15.24 | General |
| Category: Hyperkalemia | ||||||
| 11/16/2017 | Relypsa, Inc. | Veltassa (Drug) | Food and Beverage | In-kind items and services | $98.28 | General |
| Category: Hyperkalemia | ||||||
| 11/09/2017 | Keryx Biopharmaceuticals, Inc. | Auryxia (Drug) | Food and Beverage | In-kind items and services | $20.92 | General |
| Category: Nephrology | ||||||
| 11/08/2017 | Cumberland Pharmaceuticals, Inc. | Vaprisol (Drug) | Food and Beverage | In-kind items and services | $12.50 | General |
| Category: Nephrology | ||||||
| 10/17/2017 | Relypsa, Inc. | Veltassa (Drug) | Food and Beverage | In-kind items and services | $16.88 | General |
| Category: Hyperkalemia | ||||||
| 09/07/2017 | AbbVie, Inc. | — | Food and Beverage | In-kind items and services | $91.02 | General |
| 07/26/2017 | Cumberland Pharmaceuticals, Inc. | Vaprisol (Drug) | Food and Beverage | In-kind items and services | $17.23 | General |
| Category: Nephrology | ||||||
| 03/01/2017 | Cumberland Pharmaceuticals, Inc. | Vaprisol (Drug) | Food and Beverage | In-kind items and services | $17.38 | General |
| Category: Nephrology | ||||||
| 02/07/2017 | Keryx Biopharmaceuticals, Inc. | Auryxia (Drug) | Food and Beverage | In-kind items and services | $16.46 | General |
| Category: Nephrology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 211 | 449 | $143,975 | $72,076 |
| 2022 | 7 | 336 | 766 | $211,625 | $108,389 |
| 2021 | 8 | 415 | 940 | $208,582 | $110,211 |
| 2020 | 8 | 516 | 1,237 | $236,473 | $123,025 |
Total Patients
1,478
Total Services
3,392
Medicare Billing
$413,701
Procedure Codes
31
All Medicare Procedures & Services
31 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2023 | 27 | 157 | $83,210 | $41,708 | 50.1% |
| 90961 | Dialysis services, 2-3 physician visits per month (20 years or older) | Office | 2023 | 22 | 36 | $15,840 | $7,923 | 50.0% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 33 | 57 | $9,120 | $5,118 | 56.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 39 | 57 | $10,830 | $4,783 | 44.2% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 32 | 75 | $8,250 | $4,530 | 54.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 24 | 33 | $8,170 | $4,251 | 52.0% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 21 | 21 | $4,200 | $2,010 | 47.9% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 13 | 13 | $4,355 | $1,752 | 40.2% |
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2022 | 52 | 211 | $111,830 | $57,972 | 51.8% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 77 | 165 | $26,335 | $12,907 | 49.0% |
| 90961 | Dialysis services, 2-3 physician visits per month (20 years or older) | Office | 2022 | 28 | 53 | $23,320 | $12,192 | 52.3% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 68 | 183 | $20,130 | $10,004 | 49.7% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 49 | 57 | $11,400 | $5,961 | 52.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 40 | 63 | $10,920 | $5,095 | 46.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 22 | 34 | $7,690 | $4,259 | 55.4% |
| 90960 | Dialysis services (4 or more physician visits per month), patient 20 years of age and older | Office | 2021 | 43 | 156 | $80,232 | $43,018 | 53.6% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 111 | 309 | $49,440 | $24,827 | 50.2% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 94 | 256 | $28,160 | $14,224 | 50.5% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 76 | 93 | $18,600 | $9,694 | 52.1% |
| 90961 | Dialysis services (2-3 physician visits per month), patient 20 years of age and older | Office | 2021 | 15 | 30 | $12,930 | $7,031 | 54.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 35 | 49 | $7,840 | $4,825 | 61.5% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 26 | 32 | $6,880 | $4,245 | 61.7% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 15 | 15 | $4,500 | $2,347 | 52.2% |
| 90960 | Dialysis services (4 or more physician visits per month), patient 20 years of age and older | Office | 2020 | 32 | 161 | $68,908 | $36,056 | 52.3% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 150 | 385 | $61,600 | $31,523 | 51.2% |
About Dr. Thomas Ward, M.D
Dr. Thomas Ward, M.D is a Nephrology healthcare provider based in Latrobe, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/22/2006. The National Provider Identifier (NPI) number assigned to this provider is 1992770812.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Thomas Ward, M.D has received a total of $770.09 in payments from pharmaceutical and medical device companies, with $271.68 received in 2021. These payments were reported across 25 transactions from 12 companies. The most common payment nature is "Food and Beverage" ($648.84).
As a Medicare-enrolled provider, Ward has provided services to 1,478 Medicare beneficiaries, totaling 3,392 services with total Medicare billing of $413,701. Data is available for 4 years (2020–2023), covering 31 distinct procedure/service records.
Ad
Practice Information
- Specialty Nephrology
- Location Latrobe, PA
- Active Since 02/22/2006
- Last Updated 07/08/2007
- Taxonomy Code 207RN0300X
- Entity Type Individual
- NPI Number 1992770812
Products in Payments
- ACTHAR (Biological) $186.34
- Veltassa (Drug) $130.40
- RYBELSUS (Drug) $90.44
- JARDIANCE (Drug) $85.92
- Vaprisol (Drug) $61.98
- Auryxia (Drug) $37.38
- LOKELMA (Drug) $32.82
- INJECTAFER (Drug) $23.35
- LUPKYNIS (Drug) $19.69
- SAMSCA (Drug) $10.75
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.